B7H3靶向腹腔放射免疫治疗用碘标记Omburtamab治疗促纤维增生性小圆细胞肿瘤及其他腹膜肿瘤的I期研究结果
该I期研究评估了腹腔注射抗B7H3鼠单克隆抗体131I-omburtamab在促纤维增生性小圆细胞肿瘤(DSRCT)或其他表达B7H3的腹膜肿瘤患者中的安全性、药代动力学和生物分布。52例患者接受单次腹腔注射,活度从1.11递增至3.33 GBq/m2,未达到最大耐受剂量,无剂量限制性毒性,主要相关不良事件为一过性中性粒细胞减少和血小板减少及盐水输注相关疼痛。基于腹膜剂量和门诊给药可行性,推荐II期活度为2.96 GBq/m2。
要点
- 腹腔131I-omburtamab耐受良好,未达到最大耐受剂量,无剂量限制性毒性。
- 推荐II期活度为2.96 GBq/m2,基于腹膜剂量和门诊给药可行性。
- 正常器官辐射吸收剂量低,与其他抗癌治疗联合可行。
核心结论
- 腹腔放射免疫治疗131I-omburtamab耐受良好,毒性轻微,正常器官辐射暴露低,使联合其他抗癌治疗可行。
研究设计与样本
- I期研究,纳入52例患者(48例DSRCT,3例腹膜横纹肌肉瘤,1例尤文肉瘤),接受单次腹腔注射131I-omburtamab,活度从1.11递增至3.33 GBq/m2。
主要发现
- 未达到最大耐受剂量,无剂量限制性毒性。
- 主要相关不良事件为短暂性4级中性粒细胞减少(2例)和血小板减少(1例),以及盐水输注相关1级(10%)和2级(52%)疼痛,持续<2小时。
- 未观察到甲状腺功能减退,抗药抗体产生率为5%。
- 平均(±标准差)预计腹膜滞留时间为22.4±7.9小时。
- 基于124I-omburtamab剂量学,131I-omburtamab对正常器官的平均预计吸收剂量低,在可耐受范围内。
关键数值与推荐
- 推荐II期活度为2.96 GBq/m2,基于腹膜剂量和门诊给药可行性。
临床怎么用
- 腹腔131I-omburtamab可用于DSRCT或其他表达B7H3的腹膜肿瘤患者,门诊给药可行,毒性可控。
- 正常器官辐射暴露低,支持与其他抗癌治疗联合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Desmoplastic small round cell tumor (DSRCT), a rare sarcoma of adolescents/young adults primarily involving the peritoneum, has a long-term survival of < 20% despite aggressive multimodality treatment. B7H3 is expressed on DSRCT cell surface, providing a target for antibody-based immunotherapy. PATIENTS AND METHODS: In this phase I study, we evaluated the safety, pharmacokinetics, and biodistribution of intraperitoneal (IP) radioimmunotherapy (RIT) with the anti-B7H3 murine monoclonal antibody 131I-omburtamab in patients with DSRCT or other B7H3-expressing tumors involving the peritoneum. After thyroid blockade, patients received 131I-omburtamab as a single IP injection at escalated activities from 1.11 to 3.33/GBq/m2. A prior tracer dose of IP 74 MBq124I-omburtamab was used for radioimmuno-positron emission tomography imaging. Each injection was followed by IP saline infusion. RESULTS: Fifty-two patients (48, three, and one with DSRCT, peritoneal rhabdomyosarcoma, and Ewing sarcoma, respectively) received IP 131I-omburtamab administered on an outpatient basis. Maximum tolerated dose was not reached; there were no dose-limiting toxicities. Major related adverse events were transient: grade 4 neutropenia (n = 2 patients) and thrombocytopenia (n = 1), and grade 1 (10%) and grade 2 (52%) pain lasting < 2 hours related to saline infusion. Hypothyroidism was not observed, and antidrug antibody was elicited in 5%. Mean (± SD) projected peritoneal residence time was 22.4 ± 7.9 hours. Mean projected absorbed doses for 131I-omburtamab based on 124I-omburtamab dosimetry to normal organs were low and well within tolerable limits. More than 80% 131I remained protein bound in blood 66 hours after RIT. On the basis of peritoneal dose and feasibility for outpatient administration, the recommended phase II activity was established at 2.96 GBq/m2. Patients with DSRCT receiving standard whole-abdominal radiotherapy after RIT did not experience unexpected toxicity. CONCLUSION: IP RIT 131I-omburtamab was well tolerated with minimal toxicities. Radiation exposure to normal organs was low, making combination therapy with other anticancer therapies feasible.
引用
- Modak S, Zanzonico P, Grkovski M, et al. B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. J Clin Oncol. 2020. PMID: 33119478. doi:10.1200/JCO.20.01974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。